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BACKGROUND
Hereditary angioedema is a disabling, potentially fatal condition caused by deficiency 
(type I) or dysfunction (type II) of the C1 inhibitor protein. In a phase 2 trial, the use of 
CSL830, a nanofiltered C1 inhibitor preparation that is suitable for subcutaneous injec-
tion, resulted in functional levels of C1 inhibitor activity that would be expected to 
provide effective prophylaxis of attacks.
METHODS
We conducted an international, prospective, multicenter, randomized, double-blind, 
placebo-controlled, dose-ranging, phase 3 trial to evaluate the efficacy and safety of 
self-administered subcutaneous CSL830 in patients with type I or type II hereditary 
angioedema who had had four or more attacks in a consecutive 2-month period within 
3 months before screening. We randomly assigned the patients to one of four treatment 
sequences in a crossover design, each involving two 16-week treatment periods: either 
40 IU or 60 IU of CSL830 per kilogram of body weight twice weekly followed by pla-
cebo, or vice versa. The primary efficacy end point was the number of attacks of angio-
edema. Secondary efficacy end points were the proportion of patients who had a re-
sponse (≥50% reduction in the number of attacks with CSL830 as compared with 
placebo) and the number of times that rescue medication was used.
RESULTS
Of the 90 patients who underwent randomization, 79 completed the trial. Both doses of 
CSL830, as compared with placebo, reduced the rate of attacks of hereditary angioedema 
(mean difference with 40 IU, –2.42 attacks per month; 95% confidence interval [CI], –3.38 
to –1.46; and mean difference with 60 IU, –3.51 attacks per month; 95% CI, –4.21 to –2.81; 
P<0.001 for both comparisons). Response rates were 76% (95% CI, 62 to 87) in the 40-IU 
group and 90% (95% CI, 77 to 96) in the 60-IU group. The need for rescue medication was 
reduced from 5.55 uses per month in the placebo group to 1.13 uses per month in the 
40-IU group and from 3.89 uses in the placebo group to 0.32 uses per month in the 60-IU 
group. Adverse events (most commonly mild and transient local site reactions) occurred 
in similar proportions of patients who received CSL830 and those who received placebo.
CONCLUSIONS
In patients with hereditary angioedema, the prophylactic use of a subcutaneous C1 inhibitor 
twice weekly significantly reduced the frequency of acute attacks. (Funded by CSL Behring; 
COMPACT EudraCT number, 2013-000916-10, and ClinicalTrials.gov number, NCT01912456.)
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Hereditary angioedema is a dis-abling and potentially fatal condition characterized by recurrent episodes of 
swelling without urticaria or pruritus. The con-
dition is caused by deficiency (type I) or dysfunc-
tion (type II) of the C1 inhibitor protein.1 Pa-
tients have insufficient C1 inhibitor function to 
prevent bradykinin production by the contact sys-
tem, leading to episodes of increased capillary 
hyperpermeability and swelling. These episodes 
manifest clinically as angioedema attacks.2,3
Low levels of C1 inhibitor protein antigen or 
low functional levels of C1 inhibitor activity, as 
well as low levels of complement C4, are diag-
nostic for hereditary angioedema, and baseline 
C1 inhibitor function has been reported to cor-
relate with disease severity.4 According to clini-
cal observations, a sustained threshold level of 
approximately 40% functional C1 inhibitor activ-
ity has been reported to confer certain protection 
against recurrent attacks.5,6
Regular intravenous C1 inhibitor replacement 
is effective at reducing the frequency and sever-
ity of attacks and has an acceptable safety and 
side-effect profile. A double-blind, placebo-con-
trolled, crossover trial involving 22 patients with 
frequent attacks showed a 50% reduction in the 
frequency and severity of attacks with the use of 
an intravenous C1 inhibitor at a dose of 1000 IU 
twice weekly.7 However, because of the technical 
difficulties of regular venous access, risks with 
the use of indwelling venous catheters, and pa-
tient considerations,8,9 the development of a C1 
inhibitor concentrate suitable for regular subcu-
taneous administration is of interest.
A phase 2 trial showed that administration 
of CSL830 (CSL Behring), a low-volume, human 
plasma–derived, pasteurized, nanofiltered C1 in-
hibitor preparation that is suitable for subcuta-
neous injection, resulted in a dose-dependent and 
constant increase in trough plasma levels of 
functional C1 inhibitor activity above 40%,10 a 
biochemical finding expected to provide effec-
tive prophylaxis of attacks.
We describe the results of the Clinical Study 
for Optimal Management of Preventing Angio-
edema with Low-Volume Subcutaneous C1-Inhib-
itor Replacement Therapy (COMPACT), a phase 3 
trial testing the hypothesis that a twice-weekly 
subcutaneous injection of CSL830, as compared 
with placebo, could reduce the frequency of at-
tacks of hereditary angioedema in patients with 
frequent attacks.
Me thods
Trial Oversight
The trial was jointly designed by the sponsor 
(CSL Behring) and the steering committee. The 
protocol, available with the full text of this article 
at NEJM.org, was approved by the appropriate 
regulatory authorities and ethics committees or 
institutional review boards. All the patients pro-
vided written informed consent. An independent 
data and safety monitoring board regularly mon-
itored trial safety and provided recommendations 
to the sponsor on safety-related trial conduct.
The investigators at each participating center 
collected the data, which were analyzed by the 
sponsor with input from the steering committee. 
The members of the steering committee had ac-
cess to the data and vouch for the accuracy and 
completeness of the data and analyses and for 
the fidelity of the trial to the protocol. The 
manuscript was drafted by the first author and 
revised by all the authors. Medical writing assis-
tance, which was paid for by CSL Behring, was 
provided by ApotheCom.
Patients
Eligible patients were 12 years of age or older 
and had a clinical and central laboratory diagno-
sis of type I or II hereditary angioedema (func-
tional C1 inhibitor activity of <50% and C4 anti-
gen level below the normal level). All the patients 
had had four or more attacks requiring imme-
diate treatment or medical attention or causing 
clinically significant functional impairment over 
a 2-month period within 3 months before screen-
ing, as documented in the patient’s medical rec-
ords. Full inclusion and exclusion criteria are pro-
vided in Table S1 in the Supplementary Appendix, 
available at NEJM.org.
During the trial, the protocol was amended to 
include patients who were receiving oral medi-
cations for prophylaxis of angioedema attacks, 
if they had received a stable dose for 3 months 
before screening and planned to continue 
throughout the trial. Patients who had received 
an intravenous C1 inhibitor for routine prophy-
laxis within 3 months before screening were 
excluded.
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Trial Design
COMPACT was an international, prospective, 
multicenter, randomized, double-blind, placebo-
controlled, dose-ranging trial. After screening, 
eligible patients entered a run-in period of up to 
8 weeks. All the patients had a clinical diagnosis 
of hereditary angioedema that had been con-
firmed by means of central laboratory testing and 
had had at least two attacks during any con-
secutive 4-week period or at least one attack 
during the first 2 weeks of the run-in period. 
The patients were randomly assigned in a 1:1:1:1 
ratio by means of an interactive-response sys-
tem to receive CSL830 at a dose of 40 IU per 
kilogram of body weight during the first 16-week 
treatment period followed by placebo for the sec-
ond 16-week treatment period or vice versa (i.e., 
placebo first and CSL830 second); or CSL830 at a 
dose of 60 IU per kilogram followed by placebo 
or vice versa (Fig. S1 in the Supplementary Ap-
pendix).
Patients who had 12 or more attacks in a con-
secutive 4-week period (excluding the first 4 weeks 
of each treatment period) could progress to the 
next treatment period or to trial completion at 
the investigator’s discretion. An end-of-trial visit 
was scheduled 1 week after completion of the 
second treatment period or if a patient was with-
drawn from the trial.
Treatment
CSL830 or placebo was administered by the pa-
tient twice weekly in a double-blind crossover 
manner during each treatment period. Blinded 
trial medication was provided as a lyophilized 
powder to be reconstituted with sterile water for 
injection; the dose was rounded up to the near-
est milliliter per 500 IU. To maintain the blind-
ing by varying the volume of the agent that 
each patient received during the two 16-week 
treatment periods, we provided a high-volume 
placebo (matching the volume of the 60-IU 
dose of CSL830) to patients who received the 
40-IU dose of CSL830 and a low-volume placebo 
(matching the volume of the 40-IU dose of CSL830) 
to patients who received the 60-IU dose of 
CSL830.
Patients were trained to administer the injec-
tions at home. Injections were to be given by 
means of a manual slow-push method in a single 
site in the abdominal area, unless the investiga-
tor thought an alternative subcutaneous injection 
site was clinically more appropriate. Patients were 
permitted to use intravenous C1 inhibitor con-
centrate, icatibant, ecallantide, or fresh-frozen 
plasma as a rescue medication for on-demand 
treatment of attacks at any time during the trial 
or for preprocedural prophylaxis.
Clinical Assessments
Patients used an electronic diary on a daily basis 
to record symptoms, use of the trial drug, and 
any rescue therapy. The investigator reviewed the 
electronic diary at each trial visit and reported 
the details of the attack on the electronic case-
report form. Functional C1 inhibitor activity and 
C1 inhibitor and C4 protein levels were mea-
sured, and clinical laboratory assessments were 
conducted throughout the trial at specified trial 
visits (see the trial protocol).
Outcome Measures
The primary efficacy end point was the number 
of attacks of angioedema, as reported by the 
investigator. Secondary efficacy end points were 
the percentage of patients who had a response 
(≥50% reduction vs. placebo in the number of 
attacks) and the number of times that rescue 
medication was used. Exploratory end points 
included the number of days of angioedema 
symptoms, severity of attacks, and proportion of 
patients in whom the number of attacks was 
reduced to less than one attack per 4-week pe-
riod from one attack or more per 4-week period 
with placebo. The numbers of attacks and uses 
of rescue medication were normalized for the 
number of days that the patient received the cor-
responding treatment.
Safety and the side-effect profile were moni-
tored throughout the trial. Adverse events, serious 
adverse events, solicited local site reactions (in-
cluding discomfort, swelling, bruising, or itch-
ing at the injection site), the presence of inhibi-
tory anti–C1 inhibitor antibodies, results of viral 
serologic tests, and clinically significant abnor-
malities in laboratory assessments were assessed. 
In addition, a prespecified pharmacokinetic 
and pharmacodynamic analysis that was based 
on an interval-censored repeated time-to-event 
model was constructed to directly relate func-
tional C1 inhibitor activity to the attack of an-
gioedema.
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Statistical Analysis
All efficacy analyses were performed in the inten-
tion-to-treat population, which included all the 
patients who had undergone randomization. Effi-
cacy data were included from the beginning of 
week 3 for each treatment period to account for 
a run-in or washout period. The primary efficacy 
analysis was conducted without imputation for 
missing data. Safety analyses were based on the 
safety population, which included all the patients 
in the intention-to-treat population who had re-
ceived at least one dose of a study drug.
We estimated that a sample size of 72 patients 
would provide a power of 80% to detect a rela-
tive difference in the primary end point of 30% 
between the two doses of CSL830 and a power of 
99% to detect a difference between active treat-
ment and placebo at an alpha level of 0.05, assum-
ing that patients in the placebo group would 
have a mean number of 0.152 attacks per day. 
We estimated that 100 patients would need to 
undergo screening on the assumption that 20% 
of the patients would be ineligible to enter the 
treatment periods after the run-in period and that 
10% of the patients who entered the treatment 
periods would withdraw before trial completion.
Descriptive statistics were used. For the com-
parison of the number of attacks and the number 
of times that rescue medication was used, nor-
malized for the number of days that the patient 
received the corresponding treatment, a least-
squares mean difference was estimated with 
95% confidence intervals and P values with the 
use of a mixed-model accounting for the within-
patient correlation. Hypothesis testing was per-
formed hierarchically to preserve the preset level 
of significance of 0.05. Thus, we first tested the 
60-IU dose of CSL830 versus low-volume placebo, 
and only if the null hypothesis was rejected at an 
alpha level of 0.05 did we test the 40-IU dose 
versus high-volume placebo. Testing of the 60-IU 
dose versus the 40-IU dose was considered to be 
exploratory and was always tested at an alpha 
level of 0.05 for informational purposes. All sta-
tistical tests were two-sided. Statistical analyses 
were conducted with the use of SAS software, 
version 9.1.3 (SAS Institute).
R esult s
Patients
The trial was conducted from December 2013 
through October 2015. Overall, 115 patients 
were screened at 38 centers: 18 in the United 
States and 20 across Australia, Canada, the Czech 
Republic, Hungary, Israel, Italy, Romania, Spain, 
and the United Kingdom (Fig. S2 in the Supple-
mentary Appendix). Of the 90 patients who 
underwent randomization, 11 discontinued for 
various reasons (Table S2 in the Supplementary 
Appendix).
Demographic and baseline clinical character-
istics of the patients are shown in Table 1. In the 
3 months before screening, 36% of the patients 
who received 40 IU of CSL830 per kilogram and 
49% of those who received 60 IU per kilogram 
had received a prophylactic treatment to prevent 
attacks of angioedema. One of these patients 
continued to receive oral prophylaxis (danazol) 
during the trial. The mean (±SD) number of at-
tacks per month during the run-in period, nor-
malized for the number of days that the patient 
received the corresponding drug or placebo, was 
4.6±2.2 for the 40-IU treatment sequences and 
4.0±2.0 for the 60-IU treatment sequences. The 
mean duration of exposure was similar for all 
treatments: 16.3±1.6 weeks for 40 IU, 16.0±2.1 
weeks for 60 IU, and 15.3±3.3 weeks for com-
bined placebo.
Efficacy Results
Among patients who received CSL830, the rate of 
attacks of angioedema was lower than the rate 
among patients who received placebo. The mean 
difference, as compared with placebo, was –2.42 
attacks per month (95% confidence interval [CI], 
–3.38 to –1.46) with 40 IU and –3.51 attacks per 
month (95% CI, –4.21 to –2.81) with 60 IU 
(P<0.001 for both comparisons) (Table 2). No sig-
nificant difference was seen between the 40-IU 
and 60-IU treatment sequences. The occurrence 
of symptoms and the use of rescue medication 
in each patient during each treatment period are 
shown in Figure S3 in the Supplementary Ap-
pendix.
Secondary and exploratory end points are 
also listed in Table 2. In patients with data that 
could be evaluated at both doses, the median 
reduction in the normalized number of attacks 
versus placebo was 88.6% (interquartile range, 
69.6 to 100.0) with 40 IU of CSL830 and 95.1% 
(interquartile range, 79.0 to 100.0) with 60 IU. 
The percentage of patients who had a response 
was 76% in the 40-IU group and 90% in the 60-IU 
group. Overall, 43% of the patients in the 40-IU 
group and 58% of those in the 60-IU group had 
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at least a 90% reduction in attacks, and 53% of 
the patients in the 40-IU group and 71% of those 
in the 60-IU group had less than one attack per 
month. Overall, 38% of the patients in the 40-IU 
group and 40% of those in the 60-IU group did 
not have an attack, as compared with 9% and 
no patients, respectively, who received placebo. 
Patients in the 60-IU group had half as many 
attacks as those in the 40-IU group.
The average severity of attacks was lower in 
the patients who received CSL830 than in those 
who received placebo (Fig. 1). Thirteen patients 
who received CSL830 had a total of 52 severe 
attacks, and 64 patients who received placebo 
had a total of 252 severe attacks. In line with the 
observed reduction in the number of attacks re-
gardless of their location in the body, the num-
ber of patients who had laryngeal attacks was 
reduced with CSL830, with 5 patients in the 40-IU 
group, no patients in the 60-IU group, and 25 
patients in the placebo group.
The mean normalized number of times that 
rescue medication was used was reduced with 
both doses of CSL830 versus placebo (Table 2). 
The rate of use of rescue medication was 71.7% 
lower among the patients in the 60-IU group 
than among those in the 40-IU group. In the 
60-IU treatment sequences, the rate of use of 
rescue medication was lower than the rate of 
attacks.
At screening, the levels of functional C1 inhibi-
tor activity, C1 inhibitor protein, and C4 protein 
were similar across the three groups; after ran-
domization, all three biomarkers showed a dose-
dependent increase that reached steady state at 
week 3 (Fig. S4A, S4B, and S4C in the Supple-
mentary Appendix). In the population-based ex-
posure-response analysis, an inverse relationship 
Characteristic CSL830 Dose Groups
Total CSL830 
 (N = 90)
40 IU  
(N = 45)
60 IU  
(N = 45)
Age — yr 42.4±14.4 36.8±14.9 39.6±14.9
Female sex — no. (%) 28 (62) 32 (71) 60 (67)
Body weight — kg 83.0±23.0 80.2±24.6 81.6±23.7
Body-mass index† 29.5±7.3 27.7±6.8 28.6±7.1
Race — no. (%)‡
White 40 (89) 44 (98) 84 (93)
Black 3 (7) 1 (2) 4 (4)
Asian 1 (2) 0 1 (1)
Other 1 (2) 0 1 (1)
History of hereditary angioedema — no. (%)
Type I 41 (91) 37 (82) 78 (87)
Type II 4 (9) 8 (18) 12 (13)
No. of attacks of angioedema in 3 mo before screening 10.8±6.7 8.8±6.4 9.8±6.6
Use of prophylaxis against attacks of hereditary angio-
edema in 3 mo before screening — no. (%)
16 (36) 22 (49) 38 (42)
Plasma-derived C1 inhibitor 9 (20) 14 (31) 23 (26)
Oral prophylaxis 8 (18) 11 (24) 19 (21)
Danazol 6 (13) 10 (22) 16 (18)
Stanozolol 2 (4) 0 2 (2)
Oxandrolone 0 1 (2) 1 (1)
*  Plus–minus values are means ±SD. There were no significant differences at baseline between the treatment sequences 
in the characteristics shown. Percentages may not total 100 because of rounding.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  Race was reported by the patient.
Table 1. Baseline Characteristics of Patients in the Intention-to-Treat Population.*
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between the predicted functional C1 inhibitor 
activity at the time of an attack and the relative 
risk of an attack was established (Fig. 2).
 Safety and Side Effects
Adverse events were reported by similar propor-
tions of patients in the CSL830 groups and the 
placebo groups (Table 3). The majority of re-
ported adverse events were mild (in 95% of the 
patients in the 40-IU group, 76% of those in the 
60-IU group, and 83% of those in the combined 
placebo group) and were reported by the investi-
gators to be resolved by the end of the trial (98% 
of the patients in the 40-IU group, 94% of those 
in the 60-IU group, and 96% of those in the 
combined placebo group). Three adverse events 
led to trial discontinuation: pulmonary embo-
lism in a patient who received placebo, urticaria 
in a patient who received 60 IU of CSL830, and 
an increase in liver aminotransferase levels in a 
patient who received 60 IU of CSL830) (Table S2 
in the Supplementary Appendix). Four serious 
adverse events were reported in three patients: 
one event (urosepsis) in a patient who received 
the 40-IU dose and three events (pulmonary 
embolism, attack of angioedema, and syncope) 
in patients who received placebo.
Most reported adverse events were injection-
Figure 1. Attacks of Hereditary Angioedema, According to the Maximum Severity of the Attack.
The investigator graded the severity of each attack according to the intensity of the most severe symptom among 
the patients in the intention-to-treat population. Percentages may not total 100 because of rounding.
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Figure 2. Relationship between Functional Levels of C1 Inhibitor Activity 
and the Relative Risk of an Attack of Hereditary Angioedema.
The relative risk was expressed as the risk in relation to the baseline risk 
before treatment among patients with an observed geometric mean base-
line functional level of C1 inhibitor activity of approximately 25%. The red 
dashed line indicates the median of the model-based risk relationship; the 
surrounding shaded area indicates the prediction intervals (standard er-
rors). The box plots indicate the range of observed baseline and predicted 
functional levels of C1 inhibitor activity at steady-state troughs after the 
 administration of CSL830 at doses of 40 IU per kilogram and of 60 IU per 
kilogram. In each box plot, the red dot indicates the geometric mean, the 
vertical line inside the box the median, the left and right sides of the box 
the lower and upper quartiles, and the I bars the minimum and maximum 
values.
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site reactions, which occurred in 31% of the 
patients who received CSL830 and in 24% of 
those who received placebo. Of the injection-site 
reactions, 95% in the CSL830 groups and 95% 
in the placebo groups were mild; 83% in the 
CSL830 groups and 90% in the placebo groups 
resolved within 1 day after onset.
No seroconversions for the human immuno-
deficiency virus or hepatitis B or C virus were 
observed during the trial; such testing was per-
formed as a safeguard since CSL830 is a plasma-
derived product. No anaphylactic reactions or 
inhibitory anti–C1 inhibitor antibodies were de-
tected.
Discussion
In COMPACT, among patients with hereditary 
angioedema, we found that twice-weekly admin-
istration of CSL830 at doses of 40 IU per kilo-
gram or 60 IU per kilogram provided an excel-
lent and dose-dependent preventive effect, as 
evidenced across multiple trial end points. The 
median reduction in the attack rate relative to pla-
cebo was 89% with 40 IU and 95% with 60 IU 
in patients who had data that could be evaluated 
during the two 16-week treatment periods. This 
treatment effect was associated with an overall 
reduced need for rescue medication.
C1 inhibitor replacement for prophylaxis is 
currently approved only as intravenous therapy. 
Its use was first described in two case reports in 
1989.11 On the basis of a placebo-controlled study 7 
and some open-label studies,12-15 international 
guidelines recommend twice-weekly intravenous 
infusions of a C1 inhibitor preparation (1000 IU) 
for routine prophylaxis.8,16-18
A previous randomized, controlled trial in-
volving 22 patients showed the efficacy of an 
intravenous C1 inhibitor infusion regimen in pre-
venting attacks of angioedema.7 This trial showed 
a response rate (defined as ≥50% reduction in 
the frequency of attacks) of 50%.19 With the use 
of similar criteria, a response rate of 76 to 90% 
was observed in our trial.
A recent study showed that patients who re-
Event CSL830 Dose Groups
Total CSL830 
(N = 86)
Placebo 
(N = 86)
40 IU 
(N = 43)
60 IU 
(N = 43)
number of patients (percent)
Any adverse event 29 (67) 30 (70) 59 (69) 57 (66)
Any related adverse event† 14 (33) 15 (35) 29 (34) 22 (26)
Any serious adverse event 1 (2) 0 1 (1) 2 (2)
Any related serious adverse event† 0 0 0 1 (1)
Adverse event leading to trial discontinuation 0 2 (5) 2 (2) 1 (1)
Nonserious adverse event in ≥5% of patients
Injection-site reaction‡ 12 (28) 15 (35) 27 (31) 21 (24)
Nasopharyngitis 1 (2)  8 (19)  9 (11) 6 (7)
Upper-respiratory-tract infection 3 (7) 3 (7) 6 (7) 6 (7)
Hypersensitivity§ 2 (5) 3 (7) 5 (6) 1 (1)
Dizziness 4 (9) 0 4 (5) 1 (1)
Fatigue 1 (2) 1 (2) 2 (2) 6 (7)
Back pain 1 (2) 1 (2) 2 (2) 5 (6)
*  The safety analysis included all the patients in the intention-to-treat population who had received at least one dose of a study drug. Included 
are adverse events that had an onset within 24 hours after administration, which were followed until they resolved.
†  Related adverse events were adverse events that were classified by the investigator as being related to CSL830.
‡  Injection-site reactions included bruising, erythema, pain, swelling, edema, hemorrhage, and induration.
§  Hypersensitivity included pruritus, rash, and urticaria.
Table 3. Adverse Events Reported during the Trial.*
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ceived twice-weekly intravenous C1 inhibitor pro-
phylaxis had breakthrough attacks that tended 
to occur shortly before the next scheduled infu-
sion.15 These findings suggest that low trough 
levels of functional C1 inhibitor predispose a 
patient to an increased risk of an attack. When 
modeled pharmacokinetic profiles of intravenous 
and subcutaneous C1 inhibitor were compared,10 
the simulated profiles of functional C1 inhibitor 
activity showed a lower peak-to-trough ratio and 
more consistent, sustained, and higher trough 
values after subcutaneous administration than 
after intravenous administration. Therefore, the 
better treatment response rate with a subcutane-
ous C1 inhibitor may be related to a sustained 
increase in C1 inhibitor activity to a level that is 
closer to physiologic values. On the basis of the 
pharmacokinetic and pharmacodynamic model-
ing, an inverse relationship between the relative 
risk of an attack and functional C1 inhibitor ac-
tivity was established (Fig. 2). This finding sug-
gests that if the C1 inhibitor activity level could 
be maintained closer to the lower limit of nor-
mal, the risk of an attack would approach zero. 
Data are lacking on the usefulness of individual-
ized administration of C1 inhibitor replacement 
therapy to reach and maintain this target level.
The requirement for long-term, intravenous 
access with C1 inhibitor prophylaxis is a major 
clinical challenge, and despite expert advice to 
the contrary, subcutaneous ports are used, which 
can be associated with various medical compli-
cations.9 A subcutaneous C1 inhibitor may help 
to overcome many of these disadvantages.
Our trial had a limited observation period of 
14 weeks per treatment period (after the exclu-
sion of the 2-week run-in or washout period). 
Therefore, it was not possible to assess the safety 
and preventive effects of long-term continuous 
prophylaxis with CSL830. A qualitative analysis 
is under way to explore reasons for the variabil-
ity in patient responses. An open-label extension 
trial (ClinicalTrials.gov number, NCT02316353) 
is also ongoing to address this question and to 
investigate whether individual dose adjustments 
can further improve treatment response. This 
question was not addressed in the current trial.
In conclusion, we found that CSL830 signifi-
cantly lowered the rate of hereditary angioedema 
attacks, as compared with placebo. More than 
50% of the patients had no moderate-to-severe 
attacks while they were receiving CSL830.
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